NEW YORK (GenomeWeb News) – Sistemic and Roslin Cells today announced a memorandum of understanding to promote technologies to standardize the manufacture of stem cells for use in cell therapy and drug development screening.
Financial and other terms of the MOU were not disclosed.
In a statement, Jim Reid, Sistemic's CEO, said that in its work with clients, the company has found "that there is a general consensus within the stem cell community that the currently available tools and technologies are not truly fit for purpose." He added that Sistemic in collaboration with Roslin will "set the standard for stem cell characterization and quality."
Based in Glasgow, UK, Sistemic develops miRNA-based services and kit-based products for the pharmaceutical, biotechnology, and cell therapy markets. Roslin Cells is a non-profit organization established by the Roslin Institute, with the goal of providing ethically sourced, pluripotent human cells.